Pulmonary Fibrosis

Scarred lung with honeycomb holes at its edges
Scarred lung with honeycomb holes at its edges

Pulmonary fibrosis means scarring of the lungs. Over time, the delicate tissue around the tiny air sacs becomes thick and stiff, and stiff, scarred lungs cannot move oxygen into the blood as easily — so breathing slowly becomes harder. This page explains, in plain language, what pulmonary fibrosis is, what causes it, how it is diagnosed, and what treatments can do. Put plainly, it is a serious condition, the scarring that has already formed cannot be undone, and for most people it tends to worsen over time. But there are real, proven treatments that can slow it down, ease symptoms, and help you live as fully as possible — and there are warning signs that call for prompt medical assessment.


🫁 Interactive Visualization Breathing & Gas Exchange — move the diaphragm yourself Fill the alveoli and watch oxygen diffuse into the blood while carbon dioxide leaves, with live pO₂/pCO₂ meters and an exercise mode. Launch →

Table of Contents

  1. What Pulmonary Fibrosis Is
  2. Causes & Types
  3. Symptoms
  4. Diagnosis
  5. Treatment
  6. Methylene Blue and Vitamin B5 in Lung-Scarring Research
  7. Living With Pulmonary Fibrosis
  8. When to See a Doctor
  9. Key Research Papers
  10. Connections
  11. Featured Videos

What Pulmonary Fibrosis Is

Deep inside your lungs are millions of tiny balloon-like air sacs called alveoli. Their walls are extremely thin on purpose — thin enough that, with every breath, oxygen can slip across them into your bloodstream and carbon dioxide can pass out. Healthy lungs are soft and stretchy, like a fresh sponge.

In pulmonary fibrosis, the tissue between and around these air sacs becomes scarred. "Fibrosis" simply means scar tissue. Scar tissue is thick, stiff, and dense — the opposite of the soft, springy tissue lungs need. As the walls thicken and stiffen, two things happen: the lungs cannot expand as fully (so each breath holds less air), and oxygen has a harder time crossing the thickened walls to reach the blood. The result is the slow, creeping breathlessness that defines this disease.

A few honest facts to understand from the start:

The most common specific type is idiopathic pulmonary fibrosis (IPF). "Idiopathic" is a medical word that means "we don't know the cause." IPF mainly affects older adults, and most of the dedicated research and the approved medicines discussed on this page were developed for IPF.

Causes & Types

Doctors group pulmonary fibrosis by what is driving the scarring. Finding the cause matters, because it can change the treatment.

Idiopathic pulmonary fibrosis (IPF) — cause unknown

This is the most common specific type, and by definition no clear cause is found. It is thought to involve repeated tiny injuries to the lung lining in genetically susceptible people, with the lung "over-healing" into scar instead of repairing normally. IPF is most common in older adults (usually over 60) and is more common in men and in current or former smokers.

Fibrosis with a known cause or association

In many people, a cause or strong association can be identified:

Risk factors

Even when no single cause is found, several factors make fibrosis more likely:

Symptoms

Pulmonary fibrosis usually comes on gradually, and early on the signs can be easy to dismiss as "getting older" or "out of shape." The most common symptoms are:

Because these symptoms creep up slowly and overlap with many other conditions (including asthma, chronic obstructive pulmonary disease (COPD), and heart problems), pulmonary fibrosis is sometimes diagnosed later than it could be. If breathlessness or a dry cough is steadily getting worse over weeks to months, that is worth taking to a doctor — see When to See a Doctor below.

Diagnosis

There is no single blood test that diagnoses pulmonary fibrosis. Instead, doctors put together several pieces of information, and because getting the diagnosis right can be genuinely difficult, the best centers use a multidisciplinary team — a lung specialist (pulmonologist), a chest radiologist, and often a pathologist — who review the case together.

A six-minute walk test (measuring how far you can walk and whether your oxygen drops) and a check of your blood oxygen level are also commonly used — both to confirm how the disease is affecting you and to track it over time.

Treatment

There is currently no cure for pulmonary fibrosis, and no medicine can turn scar tissue back into healthy lung. What treatment can do is meaningful: for the most common type (IPF) it can slow the disease down, and across all types it can ease symptoms, treat contributing problems, and protect the lung function you still have.

Antifibrotic medicines (for IPF)

The biggest advance has been two antifibrotic drugs proven in large trials to slow the decline in lung function in IPF:

It is important to understand what "slow the decline" honestly means. These drugs do not reverse damage or make you feel suddenly better; what they do is reduce how fast lung function drops over time. They can have side effects (pirfenidone commonly causes nausea, rash, and sun sensitivity; nintedanib commonly causes diarrhea). More recently, nintedanib has also been shown (in the INBUILD trial) to slow other types of progressive lung fibrosis beyond IPF, widening who may benefit.

A third kind of medicine, nerandomilast (a phosphodiesterase 4B inhibitor taken by mouth), was tested in the FIBRONEER-IPF trial of 1,177 people with IPF, 77.7% of whom were already taking nintedanib or pirfenidone. Over 52 weeks, forced vital capacity (the amount of air a person can blow out after a full breath) fell by 114.7 ml on 18 mg twice daily, by 138.6 ml on 9 mg twice daily and by 183.5 ml on placebo. Diarrhea was the most frequent side effect (41.3% on 18 mg and 31.1% on 9 mg, against 16.0% on placebo), and serious adverse events were balanced across the groups. That trial and a companion trial in progressive pulmonary fibrosis did not meet their key secondary endpoint, but a later analysis of the pooled data (mean follow-up 16.7 months) found a lower risk of death than on placebo with both doses (hazard ratio 0.57 on 18 mg twice daily and 0.67 on 9 mg twice daily). Nerandomilast received its first approval in the United States on 7 October 2025, for adults with IPF, and a U.S. approval for progressive pulmonary fibrosis followed on 19 December 2025.

A clear warning about an older approach

For years, some doctors treated IPF with a combination of a steroid (prednisone) plus an immune-suppressing drug (azathioprine) plus the antioxidant supplement N-acetylcysteine (NAC). A major trial (PANTHER-IPF) tested this three-drug combination against placebo and found it was harmful: at a planned interim analysis, the combination group had more deaths (8 versus 1) and hospitalizations (23 versus 7) than the placebo group, and the combination arm was stopped at a mean follow-up of 32 weeks. The harm was seen with the three-drug combination; the group given N-acetylcysteine alone was compared with placebo separately and was not part of that result. This is why the three-drug regimen is no longer recommended for IPF. (Note: immune-suppressing treatment is still appropriate for fibrosis driven by an autoimmune disease — the point is that it was the wrong tool for IPF specifically.)

Supportive care (for everyone)

These measures matter as much as the medicines, and some help quality of life and survival:

Lung transplantation

For selected people — generally those who are otherwise reasonably well but whose lungs are failing despite treatment — a lung transplant can extend and improve life. It is a major operation with significant risks and lifelong medication, and not everyone is a candidate, but for the right person it is the one treatment that effectively replaces the scarred lungs. Because evaluation takes time, specialists often raise it earlier rather than later.

Methylene Blue and Vitamin B5 in Lung-Scarring Research

Searches of PubMed, Europe PMC and the ClinicalTrials.gov registry in November 2026 found no study in people of Methylene Blue or of vitamin B5 (pantothenic acid and its forms) as a treatment for pulmonary fibrosis, and no registered trial. What exists is animal research, summarised below.

Vitamin B5: two animal studies

Methylene Blue: no lung-scarring studies found

No study of Methylene Blue on pulmonary fibrosis, in people or animals, was found. Rat studies show less acute lung injury from causes such as sepsis and circulatory arrest, measured over hours to one day, before scar tissue forms. In a randomised trial of 122 hospital patients with COVID-19 lung failure in Iran, oral Methylene Blue raised oxygen saturation, with no significant difference in deaths or hospital stay; lung scarring was not measured (Sanei 2025). The studies are described on the Methylene Blue, COVID-19 and Lung Disease page.

Back to Table of Contents

Living With Pulmonary Fibrosis

A diagnosis of pulmonary fibrosis is frightening, and it is normal to feel grief, fear, and anger. Many people, though, live meaningfully for years, and there is a great deal you and your care team can do. Practical, evidence-based steps include:

For broader background on this family of conditions, see our overview of Interstitial Lung Disease.

When to See a Doctor

Make a routine appointment if you have:

Seek urgent or emergency care if you have:

For people already diagnosed, care teams can set out in advance what to do if breathing suddenly gets worse; keeping their contact details and a medication list at hand saves time.

Key Research Papers

  1. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. 2018;198(5):e44–e68. — The international guideline on how IPF is diagnosed, including the role of HRCT patterns and when a biopsy is needed. — doi:10.1164/rccm.201807-1255ST
  2. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. 2022;205(9):e18–e47. — The current treatment guideline; introduces "progressive pulmonary fibrosis" for fibrosis of other causes that keeps worsening. — doi:10.1164/rccm.202202-0399ST
  3. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (ASCEND). New England Journal of Medicine. 2014;370(22):2083–2092. — Landmark trial showing pirfenidone slows the decline in lung function in IPF. — doi:10.1056/NEJMoa1402582
  4. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis (INPULSIS). New England Journal of Medicine. 2014;370(22):2071–2082. — Twin trials showing nintedanib also slows lung-function decline in IPF. — doi:10.1056/NEJMoa1402584
  5. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases (INBUILD). New England Journal of Medicine. 2019;381(18):1718–1727. — Showed nintedanib slows progression in fibrotic lung diseases beyond IPF. — doi:10.1056/NEJMoa1908681
  6. Richeldi L, Azuma A, Cottin V, et al. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis (FIBRONEER-IPF). New England Journal of Medicine. 2025;392(22):2193–2202. — PubMed PMID: 40387033
  7. Oldham JM, Assassi S, Azuma A, et al. Effect of nerandomilast on survival in patients with pulmonary fibrosis. European Respiratory Journal. 2026. — PubMed PMID: 42532543
  8. Brown MB. Nerandomilast: First Approval. Drugs. 2026;86(4):557–563. — PubMed PMID: 41746571
  9. Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis (PANTHER-IPF). New England Journal of Medicine. 2012;366(21):1968–1977. — Found this once-common steroid/immunosuppressant/antioxidant combination increased deaths and hospitalizations in IPF; evidence against using it. — doi:10.1056/NEJMoa1113354
  10. Lederer DJ, Martinez FJ. Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 2018;378(19):1811–1823. — A clear, comprehensive review of IPF: biology, diagnosis, antifibrotic therapy, and prognosis. — doi:10.1056/NEJMra1705751
  11. Ermis H, Parlakpinar H, Gulbas G, et al. Protective effect of dexpanthenol on bleomycin-induced pulmonary fibrosis in rats. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2013;386(12):1103–1110. — PubMed PMID: 23995256
  12. Kavian N, Marut W, Servettaz A, et al. Pantethine Prevents Murine Systemic Sclerosis Through the Inhibition of Microparticle Shedding. Arthritis & Rheumatology. 2015;67(7):1881–1890. — PubMed PMID: 25776044
  13. Kavian N, Mehlal S, Marut W, et al. Imbalance of the Vanin-1 Pathway in Systemic Sclerosis. Journal of Immunology. 2016;197(8):3326–3335. — PubMed PMID: 27647831
  14. Sanei ZS, Shahrahmani F, Khaleghi Manesh B, et al. Methylene blue for COVID-19 ARDS: insights from a randomized Clinical Trial. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2025;398(2):1915–1924. — PubMed PMID: 39207597

Back to Table of Contents

Connections

Back to Table of Contents